Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,960 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti- epidermal growth factor receptor monoclonal antibody Nimotuzumab.
Arteaga ME, Ledón N, Casacó A, Pardo B, García M, Boleda M, Viña L, Orphee R, Hernández O, González C, Fuentes D, Rodríguez V, Charro L, Baro F, Macías A, Pérez A, Morales Y, Subirós N, González B, Ramos M, Rodriquez L, Ballester-Labrada A, Crombet T. Arteaga ME, et al. Among authors: ramos m. Cancer Biol Ther. 2007 Sep;6(9):1390-5. doi: 10.4161/cbt.6.9.4539. Epub 2007 Jun 5. Cancer Biol Ther. 2007. PMID: 17827980
Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma.
Casacó A, López G, García I, Rodríguez JA, Fernández R, Figueredo J, Torres L, Perera A, Batista J, Leyva R, Peña Y, Amador Z, González A, Estupiñan B, Coca M, Hernández A, Puig M, Iglesias M, Hernández A, Ramos M, Rodríquez L, Suarez N. Casacó A, et al. Among authors: ramos m. Cancer Biol Ther. 2008 Mar;7(3):333-9. doi: 10.4161/cbt.7.3.5414. Epub 2007 Dec 13. Cancer Biol Ther. 2008. PMID: 18094616 Clinical Trial.
A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.
Cetina L, Crombet T, Jiménez-Lima R, Zapata S, Ramos M, Avila S, Coronel J, Charco E, Bojalil R, Astudillo H, Bazán B, Dueñas-González A. Cetina L, et al. Among authors: ramos m. Cancer Biol Ther. 2015;16(5):684-9. doi: 10.1080/15384047.2015.1026483. Cancer Biol Ther. 2015. PMID: 25802932 Free PMC article.
Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.
Ramos TC, Figueredo J, Catala M, González S, Selva JC, Cruz TM, Toledo C, Silva S, Pestano Y, Ramos M, Leonard I, Torres O, Marinello P, Pérez R, Lage A. Ramos TC, et al. Among authors: ramos m. Cancer Biol Ther. 2006 Apr;5(4):375-9. doi: 10.4161/cbt.5.4.2522. Epub 2006 Apr 19. Cancer Biol Ther. 2006. PMID: 16575203 Clinical Trial.
Nimotuzumab: beyond the EGFR signaling cascade inhibition.
Mazorra Z, Chao L, Lavastida A, Sanchez B, Ramos M, Iznaga N, Crombet T. Mazorra Z, et al. Among authors: ramos m. Semin Oncol. 2018 Jan;45(1-2):18-26. doi: 10.1053/j.seminoncol.2018.04.008. Epub 2018 May 2. Semin Oncol. 2018. PMID: 30318080 Free article. Review.
Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.
Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernández E, Alvárez D, Torres O, Ramos M, Leonard I, Pérez R, Lage A. Crombet T, et al. Among authors: ramos m. J Clin Oncol. 2004 May 1;22(9):1646-54. doi: 10.1200/JCO.2004.03.089. J Clin Oncol. 2004. PMID: 15117987 Clinical Trial.
Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin.
Torres LA, Perera A, Batista JF, Hernández A, Crombet T, Ramos M, Neninger E, Pérez M, Sánchez EL, Romero S, Aguilar V, Coca MA, Iznaga-Escobar N. Torres LA, et al. Among authors: ramos m. Nucl Med Commun. 2005 Dec;26(12):1049-57. doi: 10.1097/00006231-200512000-00002. Nucl Med Commun. 2005. PMID: 16264350 Clinical Trial.
A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.
Rodriguez PC, Torres-Moya R, Reyes G, Molinero C, Prada D, Lopez AM, Hernandez IM, Hernandez MV, Martinez JP, Hernandez X, Casaco A, Ramos M, Avila Y, Barrese Y, Montero E, Hernandez P. Rodriguez PC, et al. Among authors: ramos m. Results Immunol. 2012 Nov 21;2:204-11. doi: 10.1016/j.rinim.2012.11.001. eCollection 2012. Results Immunol. 2012. PMID: 24371585 Free PMC article.
2,960 results